Establishment Labs Grows Revenue 44.7% and Delivers Third Straight Quarter of Positive Adjusted EBITDA
Strong Revenue Growth and Operational Leverage Drive Raised Outlook
Establishment Labs Holdings Inc. (NASDAQ: ESTA) is accelerating its growth trajectory. For the first quarter of 2026, the company reported revenue of $59.88 million, up 44.7% from the prior year’s period. Expansion in the United States, rising contributions from minimally invasive procedures, and increased global demand for Motiva implants are key factors fueling this momentum.
This performance prompted management to lift annual revenue guidance to $266.5–$268.5 million, with expectations that the minimally invasive business will exceed $35 million this year—well above earlier projections. The company also confirmed expectations for positive adjusted EBITDA each quarter and targets becoming free cash flow positive in the back half of 2026.
Margins and Profitability Signals Continue to Improve
Gross margin reached 70.7% in Q1, up from 67.2% a year ago, showing the benefits of both improved product mix and expanding scale. Despite higher sales and innovation-driven costs, operating expense grew just 8.9%, highlighting increasing operational leverage. Operating losses narrowed to $6.51 million versus a $16.95 million loss in Q1 2025, while the net loss improved to $13.38 million from $20.71 million.
Importantly, adjusted EBITDA swung to a positive $1.20 million from a $12.10 million loss a year ago—marking the company’s third consecutive profitable quarter at this level.
| Key Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue ($M) | 59.88 | 41.38 |
| Gross Margin (%) | 70.7 | 67.2 |
| Operating Expenses ($M) | 48.85 | 44.75 |
| Operating Loss ($M) | 6.51 | 16.95 |
| Net Loss ($M) | 13.38 | 20.71 |
| Adjusted EBITDA ($M) | 1.20 | -12.10 |
| Motiva U.S. Sales ($M) | 19.60 | 6.20 |
| Minimally Invasive Revenue ($M) | 9.10 | NA |
| Cash Balance ($M) | 68.10 | NA |
U.S. Launch and Minimally Invasive Platform Gain Traction
The U.S. debut of the minimally invasive platform is off to a strong start, representing almost 16% of quarterly revenue ($9.1 million) and expected to surpass $35 million for the full year—significantly ahead of prior internal targets. U.S. Motiva implant sales also continued climbing, increasing to $19.6 million in Q1, up 13.3% from Q4 2025.
Improving Cash Efficiency and Financial Flexibility
Cash used in operations dropped to $7.5 million from $21.2 million in the prior-year quarter, demonstrating greater fiscal discipline and efficiency. At quarter end, Establishment Labs’ cash balance stood at $68.1 million, supported by a recent refinancing with Oaktree that extended debt maturities and improved flexibility. Management reiterated its expectation to become free cash flow positive in the second half of 2026.
Guidance Raised: Management Expects Accelerating Growth and Profitability
Following this strong showing, the company raised its full-year 2026 outlook:
- Revenue of $266.5–$268.5 million versus prior guidance of $264–$266 million
- Minimally invasive revenue over $35 million (previously $30 million)
- Gross margin projected at 71.2%–72.2%
- Operating expenses of $195–$200 million
- Positive adjusted EBITDA each quarter, with free cash flow positive in H2 2026
Takeaway: Operational Discipline Meets Growth Ambition
Establishment Labs’ ability to sustain rapid revenue growth while narrowing losses and posting positive adjusted EBITDA suggests the company’s operating model is working as intended. The success of its U.S. initiatives and expanding minimally invasive business open the door for further margin expansion and future profitability. Investors and industry followers may want to watch for upcoming earnings calls and financial updates as the firm pushes toward consistently positive cash flow.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI